Novo Nordisk’s decision will force people in developing countries to use outdated glass vials and syringes, warn campaigners
The pharmaceutical company behind injectable weight-loss drugs has been accused of prioritising profits over the health of people in developing countries by halting production of its insulin pens.
People living with type 1 diabetes who are reliant on the human insulin produced by Novo Nordisk, will instead be given glass vials and syringes – which they say are inconvenient and harder to use with the same accuracy.
More Stories
What does Elon Musk want from all this politicking?
‘It’s desperation’: Ireland’s restaurant industry facing crisis with daily closures
Rupert Murdoch’s Dow Jones and New York Post sue AI firm for ‘illegal copying’